-
Mashup Score: 15
Background Bintrafusp alfa, a first-in-class bifunctional fusion protein targeting transforming growth factor-β (TGF-β) and programmed cell death ligand 1, has demonstrated encouraging efficacy as second-line treatment in patients with non-small cell lung cancer (NSCLC) in a dose expansion cohort of the phase 1, open-label clinical trial ([NCT02517398][1]). Here, we report the safety, efficacy, and biomarker analysis of bintrafusp alfa in a second expansion cohort of the same trial (biomarker cohort). Methods Patients with stage IIIb/IV NSCLC who were either immune checkpoint inhibitor (ICI)-naïve (n=18) or ICI-experienced (n=23) were enrolled. The primary endpoint was the best overall response. Paired biopsies (n=9/41) and peripheral blood (n=14/41) pretreatment and on-treatment were studied to determine the immunological effects of treatment and for associations with clinical activity. Results Per independent review committee assessment, objective responses were observed in the ICI-n
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 61
Background Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed after ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes of 153 patients treated with lifileucel in a large multicenter Phase 2 cell therapy trial in melanoma. Methods Eligible patients had advanced melanoma that progressed after ICI and targeted therapy, where appropriate. Melanoma lesions were resected (resected tumor diameter ≥1.5 cm) and shipped to a central good manufacturing practice facility for 22-day lifileucel manufacturing. Patients received a non-myeloablative lymphodepletion regimen, a single lifileucel infusion, and up to six doses of high-dose interleukin-2. The primary endpoint was IRC-assessed ORR (Response Ev
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Delighted that TIL are now @US_FDA approved thanks to the durable responses seen in advanced refractory melanoma and published in @jitcancer 👉https://t.co/K6hNJ3Ti8E
-
-
Mashup Score: 58
Background Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed after ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes of 153 patients treated with lifileucel in a large multicenter Phase 2 cell therapy trial in melanoma. Methods Eligible patients had advanced melanoma that progressed after ICI and targeted therapy, where appropriate. Melanoma lesions were resected (resected tumor diameter ≥1.5 cm) and shipped to a central good manufacturing practice facility for 22-day lifileucel manufacturing. Patients received a non-myeloablative lymphodepletion regimen, a single lifileucel infusion, and up to six doses of high-dose interleukin-2. The primary endpoint was IRC-assessed ORR (Response Ev
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Delighted that TIL are now @US_FDA approved thanks to the durable responses seen in advanced refractory melanoma and published in @jitcancer 👉https://t.co/K6hNJ3Ti8E
-
-
Mashup Score: 58
Background Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed after ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes of 153 patients treated with lifileucel in a large multicenter Phase 2 cell therapy trial in melanoma. Methods Eligible patients had advanced melanoma that progressed after ICI and targeted therapy, where appropriate. Melanoma lesions were resected (resected tumor diameter ≥1.5 cm) and shipped to a central good manufacturing practice facility for 22-day lifileucel manufacturing. Patients received a non-myeloablative lymphodepletion regimen, a single lifileucel infusion, and up to six doses of high-dose interleukin-2. The primary endpoint was IRC-assessed ORR (Response Ev
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Delighted that TIL are now @US_FDA approved thanks to the durable responses seen in advanced refractory melanoma and published in @jitcancer 👉https://t.co/K6hNJ3Ti8E
-
-
Mashup Score: 21Novel T cell stimulation technique drives potent anti-tumor response - 4 month(s) ago
Researchers combined an antibody with an immune-signaling molecule resulting in an agent called STAR0602. A version of the novel agent was designed for and tested in mice, which induced significant tumor shrinkage and increased survival across six different types of cancer while exhibiting little toxicity. The promising lab findings have prompted the launch of a clinical trial in people.
Source: ccr.cancer.govCategories: General Medicine News, Hem/OncsTweet-
NCI did a write up on some of our research going on at the Center for Immuno-Oncology in collaboration with Marengo. #STAR0602 @MyOncology 👉https://t.co/FwxRzVBkOc 👉STM paper here: https://t.co/moD2N0ZtRO
-
-
Mashup Score: 7Launch Your Postdoc Career with a Tenure-Track Investigator at the NCI Center for Cancer Research - 5 month(s) ago
Interested in pursuing a postdoctoral research position at NCI? Consider applying to work for a tenure-track investigator’s laboratory at the Center for Canc…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Launch Your Postdoc Career with a Tenure-Track Investigator at the NCI C... https://t.co/0aFy8QnHUc via @YouTube @NCIResearchCtr
-
-
Mashup Score: 0
A microbiologist doing cutting edge research in the microbiome space, Kylynda Bauer shares some of the work that looks at the impact of malnutrition and micr…
Source: www.youtube.comCategories: Hem/Oncs, Latest HeadlinesTweet-
See this for some very cool background from a couple years ago. https://t.co/19D4rQ3Cc5
-
-
Mashup Score: 6ASCO #GU24 Celebrates 20 Years! - 8 month(s) ago
For more information, visit https://conferences.asco.org/gu/registration
Source: www.youtube.comCategories: Hem/Oncs, Latest HeadlinesTweet-
ASCO #GU24 Celebrates 20 Years! And I am happy to report that I have attended and more importantly learned from it each year! https://t.co/k0yL4dmo4m via @YouTube @ASCO
-
-
Mashup Score: 2Advancing Digital Health Innovation in Oncology: Priorities for High-Value Digital Transformation in Cancer Care - PubMed - 8 month(s) ago
Although health care delivery is becoming increasingly digitized, driven by the pursuit of improved access, equity, efficiency, and effectiveness, progress does not appear to be equally distributed across therapeutic areas. Oncology is renowned for leading innovation in research and in care; digital …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Here today with Dr. Robinson at @CancerXMoonshot meeting at @WhiteHouse to work on ways to harness digital tools for innovation in oncology. Advancing Digital Health Innovation in Oncology: Priorities for High-Value Digital Transformation in Cancer Care https://t.co/o0G0wy7NBQ
-
-
Mashup Score: 2Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma - 8 month(s) ago
Greten TF, Abou-Alfa GK, Cheng A, et al . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. doi: 10.1136/jitc-2021-002794 On October 21, 2022, the United States (US) Food and
Source: jitc.bmj.comCategories: Latest Headlines, Oncologists1Tweet-
👉Updated HCC Guideline Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma https://t.co/BGVdk8Aw0i
-
Delighted that our paper on impact of bintrafusp alfa in NSCLC is out. Have some very long ongoing CR which limited our ability for post biopsies. Check it out 👉 https://t.co/QPhF4I6VkB